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Significant development in the reprogramming of somatic cells into induced pluripotent stem cells (iPSCs)
has been achieved by retroviral infection of defined genes. Several recent reports, including one in this issue
of Cell Stem Cell (Marson et al., 2008), have started to replace these genetic changes with specific chemical
stimulation.Cell Stem Cell 3, August 7, 2008 ª2008 Elsevier Inc. 121Direct reprogramming of both mouse and
human unipotential somatic cells to plu-
ripotent embryonic stem cell (ESC)-like
iPSCs has been realized through retroviral
transduction of four genes (Oct4, Sox2,
Klf4, and c-Myc: ‘‘OSKC’’) or through
other factor combinations (reviewed in
Yamanaka, 2007; Jaenisch and Young,
2008; Sridharan and Plath, 2008). More
recently, iPSCs have been generated
through OSK transduction alone (dis-
cussed in Knoepfler, 2008). Isolation of
iPSC colonies has been achieved through
drug selection mediated through activa-
tion of the pluripotency-specific gene
promoters, Fbx15, Oct4, or Nanog. While
Fbx15-iPSCs closely resemble Oct4- and
Nanog- iPSCs in morphology, they are
distinct in both epigenetic status and
germline competence in chimeras. A key
requirement for acquisition of pluripo-
tency is DNA methylation-mediated si-
lencing of exogenous retroviral genes
(reviewed in Jaenisch and Young, 2008).
Thus, even in c-Myc-free OSK-iPSCs
that have not been selected with drugs, it
is important to assess the state of exoge-
nous gene activity through retroviral fluo-
rescence protein marker gene expression
in order to identify suitable iPSC colonies.
The efficiency with which iPSCs are
generated is low, and little is known about
the molecular mechanisms that govern
their formation. However, recent ad-
vances have begun to shed light on the
steps that occur inside the ‘‘black box’’
of reprogramming (discussed in Sridharan
and Plath, 2008). Within 2 to 3 days of
OSKC induction, the mouse embryo
fibroblast (MEF)-specific gene, Thy1, is
repressed. This is followed by the sequen-
tial upregulation of alkaline phosphatase(AP) and stage-specific embryonic anti-
gen 1 (SSEA1) by days 3 to 4 and endog-
enous Oct4 by days 10–12 (Figure 1).
Exogenous OSKC expression decreases
shortly after activation of endogenous
Oct4. This step may be the landmark for
irreversible epigenetic reprogramming to
the iPSC phenotype. Thus, the crucial
molecular events that govern the transi-
tion from somatic cell to iPSC occur within
10–12 days of the initiating stimulus.
Generation of iPSCs for use in the
clinical setting would benefit from iden-
tification of alternative, ultimately safer,
initiating stimuli, in preference to genetic
modification. This could be transient
treatment with defined factors, low-toxic-
ity chemicals, or synthetic small mole-
cules. As a first step toward reduced reli-
ance on genetic manipulation, Melton’s
laboratory recently revealed a protocol
that overcomes the reduced efficiency of
iPSC generation when using the mini-
mized gene cocktail, OSK. As shown pre-
viously, exclusion of the c-Myc oncogene
from the reprogramming pool reduces tu-
morigenic risk in the resulting cells and
their progeny, but also lowers the reprog-
ramming efficiency of OSK-iPSCs relative
to that of OSKC-iPSCs. However, treat-
ment of the retroviral infected MEFs for
1 week with the histone deacetylase
(HDAC) inhibitor valproic acid (VPA) im-
proved the efficiency of Oct4-GFP-posi-
tive OSK-iPSC generation at 10 days by
50-fold (Huangfu et al., 2008). It was sug-
gested that the enhancing effect of VPA
on reprogramming could be due to both
upregulation of ESC-specific genes and
downregulation of MEF-specific genes.
However, the NODE repression complex
that contains HDAC activity comparableto the NuRD complex is known to repress
differentiation-related genes through as-
sociation with Oct4 and Nanog. Knock-
down of specific NODE subunits causes
ESCs to differentiate (Liang et al., 2008),
suggesting that HDAC inhibition may en-
hance stem cell differentiation due to ac-
tivation of differentiation-related genes.
Collectively, it is speculated that a key
role of HDAC inhibition in reprogramming
could be opening of MEF nuclear chroma-
tin, enabling greater accessibility to both
transcriptional activators and repressors
(Figure 1). Subtle differences in these
combinations could be envisaged to
lead cells toward different cell fates.
A further interesting advance in the
efforts to replace retroviral expression of
reprogramming genes is described by
Jaenisch and colleagues (Marson et al.,
2008, this issue). In their study, condi-
tioned media from MEFs overexpressing
Wnt3a (Wnt3a-CM) was also found to
enhance the efficiency of OSK-iPSC gen-
eration by almost 20-fold. The soluble
Wnt-induced effects were significantly
impeded by the small molecule ICG-001.
This molecule selectively represses Wnt/
b-catenin-driven genes through the dis-
ruption of b-catenin and CBP (CREB-
binding protein) interaction. Marson et al.
(2008) suggested that the signaling path-
way stimulated by Wnt3a could upregu-
late endogenous c-Myc (Figure 1). Myc
possesses global genome-binding po-
tential and functions as a key component
of active chromatin through histone H3
and H4 acetylation, and histone H3-K4
methylation, in neural stem cells (NSCs)
(Knoepfler, 2008). Therefore, both the
Wnt signaling pathway and the HDAC
inhibitor, VPA, may lead to the common
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Previewsepigenetic property of increased chroma-
tin accessibility, required for pre-iPSC
formation. It remains unclear, however,
whether Wnt3a-CM acts through the ca-
nonical Wnt-bcatenin signaling pathway.
Stabilization of b-catenin by the GSK3b
inhibitor, CHIR99021, promotes ESC
self-renewal without activation of c-Myc
(Ying et al., 2008) and may therefore func-
tion as a reprogramming enhancer. Thus,
it is possible that Wnt3a-CM enhances re-
programming efficiency through an alter-
native Wnt signaling target or pathway.
In contrast to differentiated mature B
cells, which require an additional gene to
OSKC for efficient reprogramming (Hanna
et al., 2008), adult NSCs have recently
been highlighted as a more suitable
source of cells for production of iPSCs.
Mouse adult NSCs, which naturally ex-
press endogenous Sox2 and c-Myc at
higher levels than ESCs, were readily re-
programmed into iPSCs by retroviral in-
fection of only two genes, OK (Oct4 and
Klf4) (Figure 1) (Kim et al., 2008). Further-
more, neural progenitor cells derived
from mouse fetuses were efficiently re-
programmed into iPSCs by retroviral OK
infection in the presence of the small mol-
ecule BIX-01294 (BIX), an inhibitor of the
G9a histone methyltransferase (Figure 1)
(Shi et al., 2008). BIX may facilitate up-
regulation of Oct4 through inhibition of
G9a-mediated H3K9me2, implicated in
Oct4 inactivation. Both OK and OK-BIX
iPS cells resemble ESCs in global gene
expression profile and germline compe-
tence in chimeras.
Figure 1. Generation of iPSCs with Fewer Genetic Modifications Using Chemical Stimuli
Increase of chromatin accessibility by open chromatin formation through the Wnt- and c-Myc-mediated
pathways or VPA treatment in pre-iPSCs. Reprogramming of adult neural stem cell (NSC) and fetal neural
progenitor cell (NPC) to iPSCs by two genes or two genes plus one chemical. AP, Alkaline phosphatase;
MEF, mouse embryo fibroblast; CBP, CREB-binding protein; HDAC, histone deacetylase; VPA, valproic
acid.122 Cell Stem Cell 3, August 7, 2008 ª2008 Elsevier Inc.Collectively, further advances in the
discovery of chemicals and small mole-
cules that promote epigenetic reprogram-
ming, combined with forced activation
of endogenous reprogramming genes,
could realize the goal of iPSC generation
from reprogramming-competent cells
without the requirement for genetic ma-
nipulation. Greater understanding of the
molecular mechanisms that mediate re-
programming will ultimately enable the
production of safe human iPSCs and mul-
tipotential stem cells for use in clinical
applications.
REFERENCES
Hanna, J., Markoulaki, S., Schorderet, P., Carey,
B.W., Beard, C., Wernig, M., Creyghton, M.P.,
Steine, E.J., Cassady, J.P., Foreman, R., et al.
(2008). Cell 133, 250–264.
Huangfu, D., Maehr, R., Guo, W., Eijkelenboom, A.,
Snitow, M., Chen, A.E., and Melton, D.A. (2008).
Nat. Biotechnol. 26, 795–797.
Jaenisch, R., and Young, R. (2008). Cell 132,
567–582.
Kim, J.B., Zaehres, H., Wu, G., Gentile, L., Ko, K.,
Sebastiano, V., Arauzo-Bravo, M.J., Ruau, D.,
Han, D.W., Zenke, M., and Scholer, H.R. (2008).
Nature, in press. Published online June 28, 2008.
10.1038/nature07061.
Knoepfler, P.S. (2008). Cell Stem Cell 2, 18–21.
Liang, J., Wan, M., Zhang, Y., Gu, P., Xin, H., Jung,
S.Y., Qin, J., Wong, J., Cooney, A.J., Liu, D., and
Songyang, Z. (2008). Nat. Cell Biol. 10, 731–739.
Marson, A., Foreman, R., Chevalier, B., Bilodeau,
S., Kahn, M., Young, R.A., and Jaenisch, R.
(2008). Cell Stem Cell 3, this issue, 132–135.
Shi, Y., Do, J.T., Desponts, C., Hahm, H.S.,
Scholer, H.R., and Ding, S. (2008). Cell Stem Cell
2, 525–528.
Sridharan, R., and Plath, K. (2008). Cell Stem Cell
2, 295–297.
Yamanaka, S. (2007). Cell Stem Cell 1, 39–59.
Ying, Q.L., Wray, J., Nichols, J., Batlle-Morera, L.,
Doble, B., Woodgett, J., Cohen, P., and Smith, A.
(2008). Nature 453, 519–523.
